2011 Fiscal Year Final Research Report
Development of personalized medicine for cancer chemotherapy according to a variety of sensitivity and pharmacokinetics
| Project/Area Number |
21590167
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
HAMADA Akinobu 熊本大学, 医学部附属病院, 准教授 (00322313)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAITO Hideyuki 熊本大学, 医学部附属病院, 教授 (40225727)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SASAKI Ji-i 北里大学, 医学部, 准教授 (60419637)
KAWAGUCHI Tatsuya 熊本大学, 医学部附属病院, 准教授 (50244116)
|
|---|
| Research Collaborator |
ANDO Yuichi 名古屋大学, 医学部附属病院, 准教授 (10360083)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | オーダーメード医療 / 分子標的薬 / 癌 / 薬剤反応性 |
|---|
| Research Abstract |
Objectives : We analyzed the association of ABCB1 polymorphisms with erlotinib-induced toxicity and the pharmacokinetics in patients with non-small cell lung cancer.
Methods : After erlotinib 150 mg was administered to 50 patients, ABCB1 polymorphisms were analyzed via either TaqMan assays or direct nucleotide sequencing. Plasma concentrations were measured by high-performance liquid chromatography.
Results : The trough concentration at steady state(Css) in patients with the ABCB1 1236TT-2677TT-3435TT genotype was higher as compared to others groups(P=0. 021) and this patients carrying this genotype had a higher risk of development for higher grade 2 toxicity(p=0. 012).
Conclusion : The present study suggested that the ABCB1 1236TT-2677TT-3435TT genotype was associated with higher concentration and the risk of development for higher toxicity in patients treated with erlotinib.
|
-
-
-
[Journal Article] Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small cell lung cancer2012
Author(s)
Hamada A, Sasaki J, Saeki S, Iwamoto N, Inaba M, Ushijima S, Urata M, Kishi H, Fujii S, Semba H, Kashiwabara K, Tsubata Y, Kai Y, Isobe T, Kourogi H, Saito H
-
Journal Title
Pharmacogenomics
Volume: 13
Pages: 615-624
Peer Reviewed
-
-
-
-
[Journal Article] Erlotinib efficacy and cerebrospinal fluid concentration in lung adenocarcinoma patients developing leptomeningeal metastases during gefitinib therapy2011
Author(s)
Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N
-
Journal Title
Cancer Chemother Pharmacol
Volume: 67
Pages: 1465-1469
Peer Reviewed
-
-
-
-
-
-
-
-
[Journal Article] Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia2009
Author(s)
K awaguchi T, Hamada A, Hirayama C, Nakashima R, Nambu T, Yamakawa Y, Watanabe H, Horikawa H, Mitsuya H, Saito H
-
Journal Title
Int J Hematol
Volume: 89
Pages: 642-8
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
